(Incorporated in Israel) 

We are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat severe allergies and emergency medical conditions such as anaphylaxis. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical, since the nose is lined up with a very rich vascular bed enabling quick drug absorption.

We are developing NS002,  an intranasal powder epinephrine nasal spray to treat  Type 1 severe allergies and anaphylaxis. We plan to conduct two Phase 2 trials of NS002.

We are also developing NS001, an intranasal naloxone powder nasal spray to treat opioid overdose. We intend to search for partnership opportunities to continue developing this product.

Note: Net loss and revenue are in U.S. dollars for the year that ended Dec. 31, 2024.

(Note: Nasus Pharma filed its F-1 for its small-cap IPO on July 8, 2025, and disclosed the terms – 1 million shares at a price range of $10.00 to $12.00 – to raise $11.0 million, if priced at the mid-point of its range.)